drugset / Trial / NCT00607763

Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

NCT00607763

Phase 1 Completed 9 enrolled Astellas Pharma Inc
Non-randomizedSingle-groupOpen-label

Summary

Infants and toddlers with fungal infections will receive 10 to 14 days of treatment with an antifungal drug. Safety and drug blood levels will be assessed

Timeline

Start
2007-10
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Micafungin Peptide 4.5 mg/kg Intravenous